ELUCIDATION OF PELAREOREP PHARMACODYNAMICS IN A PHASE I TRIAL IN PATIENTS WITH KRAS MUTATED COLORECTAL CANCER

KRAS mutation is a negative predictive biomarker of anti-EGFR agents in patients with metastatic colorectal cancer (mCRC), and remains an elusive target. Pelareorep, a double-stranded RNA virus selectively replicates in KRAS mutated cells, and is synergistic with irinotecan. A dose escalation trial...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer Ther
Main Authors: Goel, Sanjay, Ocean, Allyson J., Parakrama, Ruwan Y., Ghalib, Mohammad H., Chaudhary, Imran, Shah, Umang, Viswanathan, Sengottuvel, Kharkwal, Himanshu, Coffey, Matthew, Maitra, Radhashree
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7207225/
https://ncbi.nlm.nih.gov/pubmed/32156785
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-19-1117
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados